home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.09 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

35 36 Next >

Stock Market Rallies To Record High On Nvidia: Weekly Review ↗

February 23, 2024

The stock market rally pulled back to start the week, but roared higher as booming Nvidia earnings and guidance fueled big AI-led gains. The S&P 500 and Dow Jones hit... Read More

Via Investor's Business Daily

Topics Stocks

Smart Money Is Betting Big In CRSP Options ↗

February 22, 2024

Via Benzinga

Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗

February 22, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Crispr Reports Its First Profit In 10 Quarters, And Shares Fly Out Of A Buy Zone ↗

February 21, 2024

The company recently gained approval in the U.S. and abroad for its first gene-editing drug.

Via Investor's Business Daily

Check Out What Whales Are Doing With CRSP ↗

February 14, 2024

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today ↗

February 09, 2024

Via Benzinga

Got $100? 2 Top Cathie Wood Stocks to Buy and Hold. ↗

February 04, 2024

These stocks are steals right now.

Via The Motley Fool

Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought ↗

February 20, 2024

These exciting players could deliver explosive growth over time.

Via The Motley Fool

If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today ↗

February 19, 2024

It would have been a great move.

Via The Motley Fool

3 Stocks That Cathie Wood Is Loving Now: February 2024 ↗

February 16, 2024

Looking for high-growth opportunities? Here are three Cathie Wood stocks for long-term investors to consider now.

Via InvestorPlace

What's Going On With Crispr Therapeutics Stock? ↗

February 15, 2024

Crispr Therapeutics shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares have...

Via Benzinga

Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday ↗

February 15, 2024

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.

Via Benzinga

Topics Stocks

Gene therapy: Why does it cost millions for a single treatment?

February 15, 2024

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.

Via MarketBeat

Analysts see over 50% gains in these 2 mid-cap biotech stocks

February 14, 2024

The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.

Via MarketBeat

Topics Artificial Intelligence

CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ ↗

February 13, 2024

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

3 Gene Editing Stocks With Unprecedented Surge Potential ↗

February 13, 2024

While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.

Via InvestorPlace

Cathie Wood Has 37% of Her Ark Invest Portfolio Invested in These 7 Stocks ↗

February 12, 2024

The famous investor owns some huge winners -- and big losers, too.

Via The Motley Fool

3 Groundbreaking Healthcare Stocks to Buy for Robust Gains ↗

February 11, 2024

Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector.

Via InvestorPlace

3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List ↗

February 09, 2024

These strong buy healthcare stocks are among analysts' favorite picks, and their strong market position tells us why.

Via InvestorPlace

The 3 Most Undervalued Biotech Stocks to Buy in February 2024 ↗

February 08, 2024

With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.

Via InvestorPlace

2 Healthcare Stocks to Buy Hand Over Fist in February ↗

February 08, 2024

Both companies are proven innovators.

Via The Motley Fool

Cathie Wood Just Bought These 3 Biotech Stocks. Should You? ↗

February 07, 2024

They aren't all long shots, but they're all innovative.

Via The Motley Fool

2 Cathie Wood Stocks I Plan on Buying for My Kids' Portfolios ↗

February 05, 2024

These two Cathie Wood holdings are great long-term buys.

Via The Motley Fool

Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements ↗

February 01, 2024

Discover how emerging tech is shaping healthcare stocks in 2024. See which companies are outperforming and what it means for your portfolio.

Via InvestorPlace

Jim Cramer Says It's 'Still Not Too Late' To Buy This Energy Stock ↗

January 31, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is taking a "hard pass" on Surgery Partners, Inc. (NASDAQ: SGRY). "That industry has been up and down and up and down," he added.

Via Benzinga

History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does. ↗

January 30, 2024

Bull markets generally favor growth stocks, so now is a great time to buy quality growth players.

Via The Motley Fool

Topics Stocks

Is CRISPR Therapeutics a Buy in the New Bull Market? ↗

January 30, 2024

CRISPR Therapeutics is a specialist in the hot technology of gene editing.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week ↗

January 28, 2024

Wood added to her existing positions in these three exciting companies.

Via The Motley Fool

Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January ↗

January 25, 2024

These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions.

Via InvestorPlace

These 5 growth stocks are now in buy ranges

January 25, 2024

Affirm, MongoDB, UIPath, Synopsys and Crispr's charts signal buy opportunities as these top-performing tech and biotech stocks consolidate below prior highs.

Via MarketBeat

Topics ETFs

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com